https://www.marketscreener.com/quote/stock/GENEURO-SA-27100923/news/GeNeuro-Will-Present-Phase-IIb-Safety-and-Efficacy-Data-on-Temelimab-from-its-ProTEct-MS-Study-at-th-42078544/?utm_source=telegram&utm_medium=social&utm_campaign=share